{
  "query": "AZN",
  "resolved": {
    "ticker": "AZN",
    "cik": "0000901832",
    "title": "ASTRAZENECA PLC"
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE1 primary completion in ~105 days",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE1)",
        "detail": "A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants",
        "nctId": "NCT07723833",
        "date": "2026-11-18"
      },
      "observed": {
        "event": "primary completion in ~105 days",
        "nctId": "NCT07723833"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 2 readout / advance",
        "leadTime": "12-24 mo",
        "baseRate": 0.52,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 52% (Wong/Siah/Lo 2019)",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07723833",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — trial primary completion in ~57 days",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (n/a)",
        "detail": "A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs",
        "nctId": "NCT05663515",
        "date": "2026-10-01"
      },
      "observed": {
        "event": "primary completion in ~57 days",
        "nctId": "NCT05663515"
      },
      "predicted": {
        "event": "SEC 8-K / press release (material trial update)",
        "leadTime": "days–weeks",
        "baseRate": null,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "days–weeks to disclosure",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT05663515",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE1 primary completion in ~177 days",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE1)",
        "detail": "A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC",
        "nctId": "NCT07000149",
        "date": "2027-01-29"
      },
      "observed": {
        "event": "primary completion in ~177 days",
        "nctId": "NCT07000149"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 2 readout / advance",
        "leadTime": "12-24 mo",
        "baseRate": 0.52,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 52% (Wong/Siah/Lo 2019)",
      "confidence": 0.55,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07000149",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — trial protocol updated 1 days ago",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (n/a)",
        "detail": "Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China",
        "nctId": "NCT07161388",
        "date": "2028-09-30"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT07161388"
      },
      "predicted": {
        "event": "SEC 8-K / press release (material trial update)",
        "leadTime": "days–weeks",
        "baseRate": null,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "days–weeks to disclosure",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07161388",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — trial protocol updated 1 days ago",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (n/a)",
        "detail": "A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.",
        "nctId": "NCT07743944",
        "date": "2031-08-04"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT07743944"
      },
      "predicted": {
        "event": "SEC 8-K / press release (material trial update)",
        "leadTime": "days–weeks",
        "baseRate": null,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "days–weeks to disclosure",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07743944",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 1 days ago",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin",
        "nctId": "NCT07664553",
        "date": "2028-05-23"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT07664553"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07664553",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 1 days ago",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus",
        "nctId": "NCT07662044",
        "date": "2028-07-14"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT07662044"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07662044",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 1 days ago",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin",
        "nctId": "NCT07662135",
        "date": "2028-07-13"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT07662135"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07662135",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "ASTRAZENECA PLC (AZN) — PHASE3 protocol updated 1 days ago",
      "entity": "AstraZeneca",
      "ticker": "AZN",
      "cik": "0000901832",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus",
        "nctId": "NCT07662109",
        "date": "2028-07-05"
      },
      "observed": {
        "event": "protocol updated 1 days ago",
        "nctId": "NCT07662109"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07662109",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000901832&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "ASTRAZENECA PLC",
    "sicDescription": "Pharmaceutical Preparations",
    "filings": []
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-08-05T09:00:27.014Z"
}